Not Yet Recruiting
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
NCT06028633
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer
- Locations
-
- Peking University First Hospital Ethics Committee Beijing, Beijing Municipality, China